23andMe Gets NHGRI Grant

23andMe will use the funding to research genetic factors underlying responses to three drug classes — non-steroidal anti-inflammatory drugs, protein-pump inhibitors used to treat gastroesophogeal reflux disease, and the blood thinner warfarin.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories